Across TCGA pan-cancer cohorts, ZBTB2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ZBTB2’s most consistent transcriptional readouts.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ZBTB2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ZBTB2 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.
PDAC, CCRCC, and LUAD are the cancer types where ZBTB2 tumor–normal differential expression is most reproducible.